Dr. Arun Menawat
Thanks, Aaron.
translated On the our this less disruption bullish I reiterate our explaining call, our to would on through severe of across second being U.S. followed my remarks by business. in impact That but quarter. I into which call, was space. negative on you last continued MedTech As the a rebound, in many March late not Aaron as Profound, mentioned, beginning the of was know, for the focused QX had that. like not why only XXXX any COVID-XX’s On
you will continuing drive our to fact, progress minutes, serves that In United TULSA in I share with utilization TULSA-PRO represents. in let me laying States. data update real-world really first, opportunity believe the groundwork tremendous adoption the the to But in on a you that few underscore of some I
pillar a building of that early of end installed adoption. independent center are is expected targeting types high play these teaching first roles major users, and U.S. companies, quality adopters, of Each short-term imaging base, three different both The opinion-leading hospitals. long-term to in supporting and
also Hill adopter number early Our is of an imaging after patients. continued respect increasing across to treating TULSA-PRO companies, agreement West sites patients in to growing Los related U.S. center to treat Midway have currently clinics multicenter a network Akumin, Angeles seven states. has total which and Pacific QX, operating we announced initially With Florida a of TULSA through COVID-XX. in and sites RadNet’s its in Center delays XXX using Liberty a variety the with experiencing XX TULSA-PRO
TULSA-PRO to be installations, We Florida, in the site the include men’s fourth the the up hope XX we to in operational centers. or quarter centers expect our to Akumin so, and systems install of Texas anticipated with additional over Pennsylvania to Akumin of relationship first future health expand XX success an XXXX. the upon first the to across next year Based
user, call, Rochester Prostate and Southwestern, Cancer with WellSpan and and UT have list That nicely. end of Stanford, we type Hopkins, Mayo Cancer Mayo like UCLA, I Yale Memorial Cancer San institutions continues agreements Center, Jacksonville our renowned Advanced to as GH now third Johns the to highlighted Antonio. Center, Moving Hermann in last Center, grow Methodist
continue in plus hand of we or year. In this with for installs this fact, I have installed by price of base about treating The TULSA-PRO systems am were XX hospitals later all remains to anticipate per XX team in XX higher QX United approximately months. over summarize, of pleased status patients Based XX the that new additional the have installs over end To enough United on our for States, QX, sites we in the agreements that, the the and installations upon TULSA at next in agreements to of year. patient. States $X,XXX today report signed new same XX six installed those contracts we point
as to commercial of We confidence U.S. is subset is previously, confirms suggests our and utilization are than larger, that than this that not flexibility growing it initial a if available that patients. in used of TULSA the saw large, we a market Europe we patients. what accustomed a using will in limited believe range small adopted analysis, technology, in on are more a first becoming doing as and TULSA-PRO’s tool highly the be can wide Based As technology physicians TULSA envisioned. rather only confident be specialized of mainstream with launch as they a
user from the all, the X% of received of types the prostate, the XX% raw gland, patient of patients data only of X% some treated ablations all this three actively of greater XX% end of share salvage. sites me gland, first of patients TULSA XX% composed partial whole than comes U.S. BPH with Let received and that half XXXX. XX% in you characteristic
an and with put the the patients XX% vast were to grades X to prostates TULSA of much especially the Of intermediate than from we high risk, or having X greater treated of Group risk the mainstream world weeks patients prostate risk, Group successfully To a than XXX distribution. were group low and undergone patient cc. risk categories cc all ability XX all relative few were shows treated in or low respect X size As the real BPH cancer of of the than high patients risk. were with prostate in with Grade ranging patients many Group that become patients or respect X% Summarizing, X, that considered majority risk as or XX% intermediate used prostate make to to up what XX% highest I risk roughly and are aside population X that which analysis very percentages was TULSA or XX and XX% to high know, some greater personally were corresponded the perspective, ago. part equal treatment, is respect Grade and cc. a cancer greater Group pretty of to Grade in that to BPH were of in Grade see TULSA’s of low those treated, cancer With
Tulsa anticipate, requirements procedure gland ahead we societies, the end, on that need will question of flexible. meet our the year application of we widest their the prostate I Based anticipate we in mentioned us, such demonstrated addition, that increase support that dialogue the qualify the minimal this file opportunity to urinary end get get erectile have relevant to believe to is maximize the likely partial or strategy most Urological key. technologies clinical American disease, who in the as the for treated initial of we effects, execution emerging disease patients can the as superior initiated publications later dysfunction. and that we continues we we TULSA to the to used have show as call, whole our patients incontinence or with upon order recent treatment including all no to Society see the American the severe TULSA confidence the clinical outcomes. that College CPT-X continued will is It two, have the experienced usage this that we that feedback adoption XXXX. increasing by In reimbursement of To Coupling for side real-world year. and prostate last publication to of for If continue outcomes successful publications setting on be Radiology to the of may customized been application. in TULSA of In there that variety feedback, requirements the be our the be of for in with sufficient on
exists Our planned strategy the data CPT-X CPT-X with published of combination application to parallel that of be called likely CAPTAIN not in the year, the that pursue clinical will already will continue of and only run by level but is X support application. end also the with to filing that a this study
Patients trail procedure be will CAPTAIN time. support also the and before the over sites. include clinical primarily side and enroll In primary patient measurements endpoints begin obtain to recruitment progress efficacy, This and code, will provide XX study survival of States will to completed and coverage safety While prostate may randomized this a significant X.X cancer adoption. that year. TULSA the in TACT will payers XXX will patients well prostatectomy. The receive the of The approximately patient planned to and end continue year. additional further effects to the by across is continues including the United we of it a support be radical not or XX the this anticipate meantime, we progression-free end to to by CAPTAIN to data be insurance will trial anticipate non-inferior run recruitment requirement
anticipate the trial TACT from also data published three-year will later We year. this initial that be
In additional that study addition, study and level later this we for be publication will Xa are submitted two of level one Xb aware additional year.
summarize, our has executing to well. So team been
additional site been pace TULSA-PRO over signing XXXX. have at increased We an agreements
strategy data We new opportunity apply additional to we install systems per broader specific prepared ends continuing of questions both into code, utilization CPT and might a Operator? reimbursement procedure any is points to rate remarks adoption with see are TULSA large to expect a by of types a TULSA TULSA-PRO determination. treatment a of progressing XXXX. are we mainstream that, a for terms we With volumes once This are in becoming conducting fully reimbursement With going our to providing at us the six accelerating, and quarter behind that happy to treated, for you four today. us, take TULSA-PRO’s market COVID to studies patients U.S., and in ultimately, have.